NeuroSense Therapeutics Ltd. (NRSN)

NASDAQ: NRSN · Real-Time Price · USD

0.8089

+0.0584 (7.78%)

At close: Apr 28, 2026, 4:00 PM EDT

0.7909

-0.0180 (-2.23%)

After-hours: Apr 28, 2026, 6:19 PM EDT

NeuroSense Therapeutics Earnings Call Transcripts

Fiscal Year 2025

Status Update

PARAGON phase III ALS trial is set to begin mid-2026, with FDA clearance and global enrollment plans. New data and biomarkers will support regulatory submissions, while partnership and financing efforts are ongoing. The Alzheimer's program has completed phase II data collection, with results expected in Q1 2026.

Read full transcript →